Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Senzime AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -960.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Senzime AB's 3-Year ROIIC % or its related term are showing as below:
FRA:6YC's 3-Year ROIIC % is ranked worse than 98.36% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs FRA:6YC: -960.02
Senzime AB (FRA:6YC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Senzime AB 3-Year ROIIC % Related Terms
Senzime AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Senzime AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6YC vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Senzime AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Senzime AB's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Senzime AB (FRA:6YC) has a 3-Year ROIIC % of -960.02 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Senzime AB and its competitors. According to the industry distribution chart, Senzime AB ranks #782 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 98.4%.
Is Senzime AB's 3-Year ROIIC % too high?
Senzime AB's current 3-Year ROIIC % is -960.02. Based on the distribution chart, Senzime AB ranks #782 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Senzime AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #782 out of 795 companies for 3-Year ROIIC %. This places Senzime AB in the lower half of its industry. The industry median 3-Year ROIIC % is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current 3-Year ROIIC % is -960.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Senzime AB (FRA:6YC) has a current 3-Year ROIIC % of -960.02. The stock's GF Value™ is €0.73, compared to a current price of €0.32 — trading 56.5% below its estimated fair value. The current 3-Year ROIIC % is -960.02. Senzime AB's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Senzime AB (FRA:6YC), the current 3-Year ROIIC % is -960.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (FRA:6YC) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of €0.32 is trading 56.5% below its estimated GF Value™ of €0.73.
Key valuation signals for FRA:6YC:
3-Year ROIIC %: -960.02
GF Value™: €0.73 vs. price of €0.32 (56.5% below fair value)
No single metric tells the full story. See the FRA:6YC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
71GF Score
Get the complete analysis for FRA:6YC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YC has been successfully added to your 
